Slides
Page 1
1 Earnings Presentation Q2/H1-FY27
Page 2
2 62 + YEARS OF EXPERTISE OPERATIONS IN 50 + COUNTRIES 360° TOTAL WATER & ENVIRONMENT MANAGEMENT WORLD CLASS MANUFACTURING FACILITIES ONE OF ASIA’S LARGEST SERVICE NETWORKS SERVING INDUSTRIES, INSTITUTIONS, HOMES & COMMUNITIES GLOBAL ASSEMBLY HUBS IN UAE, SAUDI ARABIA, SOUTH AFRICA, INDONESIA & BANGLADESH ADVANCED R&D CENTRES IN INDIA COMMITTED TO SUSTAINABILITY Company Snapshot 200,000 + INSTALLATIONS WORLD-WIDE 3,000 + CORE INDUSTRY PROJECTS EXPORTS ACROSS CONTINENTS
Page 3
3 Total Water & Environment Management Solutions Management of Process Water Specialty Resins / Adsorbents / Membranes / Chemicals / Enzymes for Purification & Concentration Industrial Wastewater Treatment Recycle & Zero Liquid Discharge Drinking Water Treatment Sewage Treatment, Tertiary Sewage Recycle, Sludge Management Pretreatment Process Water Treatment – Ion Exchange & Membrane Based
Page 4
4 ZERO LIQUID DISCHARGE Leaders in Resins, Membranes & Chemicals, with a Unique End-to-End Portfolio Spanning Solutions, Digital & Services PROCESS WATER TREATMENT HIGH PURITY WATER ULTRA PURE WATER INDUSTRIAL WASTEWATER TREATMENT 1 2 3 4 5 7 8 DRINKING WATER SOLUTIONS SOURCE WATER & PRETREATMENT MUNICIPAL & SEWAGE TREATMENT 6 Capabilities RESINS MEMBRANES CHEMICALS SOLUTIONS SERVICES DIGITAL
Page 5
5 50+ COUNTRIES SERVED 30% INTERNATIONAL REVENUE SHARE 14 GLOBAL MANUFACTURING FACILITIES & ASSEMBLY CENTRES GLOBAL INSTALLATIONS 200,000+ Our Global Offices Global Presence
Page 6
6 Ankleshwar, Gujarat Resins Manufacturing - Exports Verna, Goa Centre of Membrane Excellence Roha, Maharashtra Non-Solvent Resins Patancheru, Telangana Chemicals Manufacturing Portugal MAPRIL, Manufacturing Facility Saudi Arabia Chemical Blending Facility Global Manufacturing Facilities
Page 7
7 Hosur, Tamil Nadu Standard Systems Assembly Wada, Maharashtra Standard Systems Assembly UAE Assembly Unit, ICV Certified Facility Indonesia Assembly and Testing Center Bangladesh Fabrication Unit & Assembly Centre South Africa Manufacturing Facility Palaspe, Maharashtra Large System Assembly Verna, Goa Standard Membrane Systems Global Manufacturing Facilities
Page 8
8 Ion Exchange (India) Ltd. Current Reporting Treatment Solutions Industrial Products Lifecycle Services Specialty Chemicals Consumer Products Current vs New Reporting Segments New Reporting Institutional Engineering Chemicals Consumer Products
Page 9
9 CONSUMER PRODUCTS INDUSTRIAL PRODUCTS LIFECYCLE SERVICES TREATMENT SOLUTIONS SPECIALTY CHEMICALS New Reporting Segments ▪ Water Treatment ▪ Ultra Pure Water ▪ High Purity Water ▪ Desalination ▪ Wastewater Treatment & Recycle ▪ Zero Liquid Discharge (ZLD) ▪ PFAS ▪ Standard Water Treatment Solutions ▪ Membranes (RO, UF , NF , MBR) ▪ Institutional Water Treatment Products ▪ Operations & Maintenance (O&M) ▪ Rehabilitation & Modification ▪ Spares, Services & Consumables ▪ BOO/BOOT/WaaS ▪ Rentals ▪ Audits ▪ Remote Monitoring ▪ Water Treatment Chemicals ▪ Utility Chemicals ▪ Process Chemicals ▪ Membrane Chemicals ▪ Polymers ▪ Resins ▪ Industrial ▪ Process ▪ Pharma ▪ Home Water Solutions ▪ Community Water Treatment Solutions ▪ Wellness ▪ Hydrogen Water ▪ Alkaline Water 1 2 3 4 5
Page 10
10 Financial Overview Q2/H1-FY27
Page 11
11 Q2-FY27 Financial Highlights Q2-FY27 Performance (Standalone) Q2-FY27 Performance (Consolidated) Engineering projects^ ~ INR 26,960 Mn Total Orderbook ~ INR 29,690 Mn Outstanding Sri Lanka ~ INR 100 Mn Outstanding UP SWSM ~ INR 2,630 Mn Bid Pipeline ~ INR 93,700 Mn Order Book and Pipeline (As on 30 September, 2026) for Treatment Solutions, Industrial Products & Lifecycle Services ^Excluding Sri Lanka Order and UP SWSM. INR 6,157 Mn Operating Income INR 6,747 Mn Operating Income INR (773) Mn Operating EBITDA INR (848) Mn Operating EBITDA (12.55) % Operating EBITDA Margins (12.57) % Operating EBITDA Margins INR (714) Mn Net Profit INR (828) Mn Net Profit (11.60) % PAT Margins (12.27) % PAT Margins INR (5.804)/ Share Diluted EPS INR (6.837)/ Share Diluted EPS
Page 12
12 H1-FY27 Financial Highlights H1-FY27 Performance (Standalone) H1-FY27 Performance (Consolidated) INR 12,513 Mn Operating Income INR 13,752 Mn Operating Income INR (467) Mn Operating EBITDA INR (530) Mn Operating EBITDA (3.73) % Operating EBITDA Margins (3.85) % Operating EBITDA Margins INR (600) Mn Net Profit INR (797) Mn Net Profit (4.80) % PAT Margins (5.80)% PAT Margins INR (4.877) / Share Diluted EPS INR (6.490) / Share Diluted EPS
Page 13
13 Treatment Solutions Quarterly/Half Yearly Segmental Breakup INR Mn INR Mn Standalone Consolidated 2,901 1,430 72 (1,139) Q2-FY26 Q2-FY27Revenue EBIT 2,958 1,498 (122) (1,215) Q2-FY26 Q2-FY27Revenue EBIT 4,797 3,597 46 (1,389) H1-FY26 H1-FY27 Revenue EBIT 4,633 3,440 256 (1,321) H1-FY26 H1-FY27 Revenue EBIT
Page 14
14 Industrial Products Quarterly/Half Yearly Segmental Breakup INR Mn INR Mn Standalone Consolidated 1,009 1,360 74 86 Q2-FY26 Q2-FY27 Revenue EBIT 1,931 2,411 124 210 H1-FY26 H1-FY27 Revenue EBIT 974 1,342 102 111 Q2-FY26 Q2-FY27Revenue EBIT 1,858 2,397 148 247 H1-FY26 H1-FY27 Revenue EBIT
Page 15
15 Lifecycle Services Quarterly/Half Yearly Segmental Breakup INR Mn INR Mn Standalone Consolidated 770 706 231 59 Q2-FY26 Q2-FY27 Revenue EBIT 1,329 1,422 289 130 H1-FY26 H1-FY27 Revenue EBIT 659 611 31 60 Q2-FY26 Q2-FY27Revenue EBIT 1,127 1,197 71 122 H1-FY26 H1-FY27 Revenue EBIT
Page 16
16 Specialty Chemicals Quarterly/Half Yearly Segmental Breakup INR Mn INR Mn Standalone Consolidated 2,181 2,546 629 225 Q2-FY26 Q2-FY27 Revenue EBIT 4,070 4,843 1,091 448 H1-FY26 H1-FY27 Revenue EBIT 1,827 2,138 537 233 Q2-FY26 Q2-FY27 Revenue EBIT 3,297 3,999 948 480 H1-FY26 H1-FY27 Revenue EBIT
Page 17
17 Consumer Products Quarterly/Half Yearly Segmental Breakup INR Mn INR Mn Standalone Consolidated 771 1,005 (23) (41) Q2-FY26 Q2-FY27 Revenue EBIT 1,613 2,129 (27) (45) H1-FY26 H1-FY27 Revenue EBIT 771 1,005 (24) (43) Q2-FY26 Q2-FY27 Revenue EBIT 1,613 2,129 (29) (47) H1-FY26 H1-FY27 Revenue EBIT
Page 18
18 Q2/H1-FY27 Operational Highlights Treatment Solutions: ▪ Change in the estimated cost to complete a few legacy projects in the Treatment Solutions segment has significantly impacted the Company financials for this quarter. ▪ Turnover for Treatment solutions was impacted by the execution of certain high-value contracts being scheduled for H2. Dispatches to GCC markets were delayed due to the ongoing Middle East crisis. Industrial Products: ▪ Industrial Products delivered strong growth during the quarter, recording an increase of approximately 35% YoY. Lifecycle Services: ▪ Lifecycle services recorded sequential growth during the quarter, while maintaining stable margins. Specialty Chemicals: ▪ Specialty Chemicals recorded sequential and YoY improvement in turnover during the quarter. ▪ Margins remained under pressure due to input cost inflation arising from the West Asia crisis and costs associated with the Roha facility. ▪ Improved cost pass-through to customers is expected to support margin recovery in the coming months. Consumer Products: ▪ Consumer Products segment continued to deliver strong volume growth during the quarter. Other Updates: ▪ Our Advanced Digital solutions offerings is seeing encouraging response, and this segment will positively impact our financial profile in the future. ▪ The Company has significantly invested in strengthening the organisation structure in the overseas geographies. This has improved our market reach, and we expect the benefits to accrue in the coming months.
Page 19
19 Future Growth Drivers Treatment Solutions: ▪ In Treatment solutions segment, a strong order backlog and planned execution schedules are expected to drive an improvement in H2 turnover, accompanied by a better margin profile. Industrial Products: ▪ Healthy order inflows are expected to sustain the Industrial Products segment's growth momentum in the coming quarters. Specialty Chemicals: ▪ Offtake from the new resin manufacturing facility at Roha is gradually improving and is expected to contribute increasingly to segment growth. Consumer Products: ▪ Continued investments in the consumer products segment are aimed at significantly scaling up the business and expanding its revenue base.
Page 20
20 Quarterly Consolidated Financial Performance INCOME STATEMENT (INR Mn) Q2-FY27 Q2-FY26 Y-o-Y Q1-FY27 Q-o-Q Operating Income 6,747 7,339 (8.1)% 7,005 (3.7)% Expenses 7,595 6,654 14.1% 6,687 13.6% Operating EBITDA (848) 685 NA 318 NA Operating EBITDA Margins (%) (12.57)% 9.33% NA 4.54% NA Depreciation 220 122 80.3% 218 0.9% Finance Cost 94 31 NA 90 4.4% Other Income 78 143 (45.5)% 60 30.0% PBT before Exceptional Items (1,084) 675 NA 70 NA Exceptional Items - NA NA - NA PBT (1,084) 675 NA 70 NA Share of Profit of equity accounted Investee 9 4 NA 4 NA Tax (247) 180 NA 43 NA Profit After Tax (828) 499 NA 31 NA PAT Margins (%) (12.27)% 6.80% NA 0.44% NA Other Comprehensive Income 8 27 (70.4)% 3 NA Total Comprehensive Income (820) 526 NA 34 NA Diluted EPS (INR)# (6.837) 4.178 NA 0.347 NA #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No of Shares: 43,78,740)
Page 21
21 Quarterly Standalone Financial Performance #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) INCOME STATEMENT (INR Mn) Q2-FY27 Q2-FY26 Y-o-Y Q1-FY27 Q-o-Q Operating Income 6,157 6,782 (9.2)% 6,356 (3.1)% Expenses 6,930 6,174 12.2% 6,049 14.6% Operating EBITDA (773) 608 NA 307 NA Operating EBITDA Margins (%) (12.55)% 8.96% NA 4.83% NA Depreciation 206 110 87.3% 203 1.5% Finance Cost 86 22 NA 82 4.9% Other Income 103 165 (37.6)% 132 (22.0)% PBT before Exceptional Items (962) 641 NA 154 NA Exceptional Items - NA NA - NA PBT (962) 641 NA 154 NA Tax (248) 162 NA 40 NA Profit After Tax (714) 479 NA 114 NA PAT Margins (%) (11.60)% 7.06% NA 1.79% NA Other Comprehensive Income (1) (1) NA (1) NA Total Comprehensive Income (715) 478 NA 113 NA Diluted EPS (INR)# (5.804) 3.894 NA 0.927 NA
Page 22
22 Half-Yearly Consolidated Financial Performance INCOME STATEMENT (INR Mn) H1-FY27 H1-FY26 Y-o-Y Operating Income 13,752 13,171 4.4% Expenses 14,282 11,861 20.4% Operating EBITDA (530) 1,310 NA Operating EBITDA Margins (%) (3.85)% 9.95% NA Depreciation 438 244 79.5% Finance Cost 184 56 NA Other Income 138 320 (56.9)% PBT before Exceptional Items (1,014) 1,330 NA Exceptional Items - NA NA PBT (1,014) 1,330 NA Share of Profit of equity accounted Investee 13 8 62.5% Tax (204) 354 NA Profit After Tax (797) 984 NA PAT Margins (%) (5.80)% 7.47% NA Other Comprehensive Income 11 47 (76.6)% Total Comprehensive Income (786) 1,031 NA Diluted EPS (INR)# (6.490) 8.286 NA #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No of Shares: 43,78,740)
Page 23
23 Half-Yearly Standalone Financial Performance #Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Sharehold ing (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) INCOME STATEMENT (INR Mn) H1-FY27 H1-FY26 Y-o-Y Operating Income 12,513 11,961 4.6% Expenses 12,980 10,791 20.3% Operating EBITDA (467) 1,170 NA Operating EBITDA Margins (%) (3.73)% 9.78% NA Depreciation 409 220 85.9% Finance Cost 168 38 NA Other Income 236 360 (34.4)% PBT before Exceptional Items (808) 1,272 NA Exceptional Items - - NA PBT (808) 1,272 NA Tax (208) 324 NA Profit After Tax (600) 948 NA PAT Margins (%) (4.80)% 7.93% NA Other Comprehensive Income (3) (1) NA Total Comprehensive Income (603) 947 NA Diluted EPS (INR)# (4.877) 7.708 NA
Page 24
24 Historical Financial Overview
Page 25
25 Historical Standalone Financial Performance INCOME STATEMENT (INR Mn) FY23 FY24 FY25 FY26 H1-FY27 Operating Income 18,923 21,800 25,401 26,789 12,513 Expenses 16,544 19,129 22,549 24,946 12,980 Operating EBITDA 2,379 2,671 2,852 1,843 (467) Operating EBITDA Margins (%) 12.57% 12.25% 11.23% 6.88% (3.73)% Depreciation 281 330 400 576 409 Finance Cost 90 67 84 205 168 Other Income 450 470 512 950 236 PBT before Exceptional Items 2,458 2,744 2,880 2,012 (808) Exceptional Items - - - 145 - PBT 2,458 2,744 2,880 1,867 (808) Tax 607 703 735 483 (208) Profit After Tax 1,851 2,041 2,145 1,384 (600) PAT Margins (%) 9.78% 9.36% 8.44% 5.17% (4.80)% Other Comprehensive Income (23) (9) (1) (6) (3) Total Comprehensive Income 1,828 2,032 2,144 1,378 (603) Diluted EPS (INR) @ 15.060 16.603 17.447 11.257 (4.877) @Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140)
Page 26
26 PARTICULARS (INR Mn) FY25 FY26 H1-FY27 EQUITIES & LIABILITIES Equity (A) Equity Share Capital 147 147 147 (B) Other Equity 12,556 13,750 12,994 Total Equity 12,703 13,897 13,141 Non-Current Liabilities (A) Financial Liabilities (i) Borrowings 1,980 3,082 2,706 (ii) Lease Liabilities 125 160 146 (iii) Other financial Liabilities 134 124 111 (B) Provisions 173 263 263 Total Non – Current Liabilities 2,412 3,629 3,226 Current Liabilities (A) Financial Liabilities (i) Borrowings 290 760 1,008 (ii) Lease Liabilities 46 97 93 (iii) Trade Payables 7,346 8,468 8,169 (iv) Other Financial Liabilities 891 817 1,118 (B) Other Current Liabilities 5,071 4,644 5,836 (C) Provisions 68 223 323 (D) Liabilities for current tax (Net) 87 69 - Total Current Liabilities 13,799 15,078 16,547 GRAND TOTAL - EQUITIES & LIABILITES 28,914 32,604 32,914 PARTICULARS (INR Mn) FY25 FY26 H1-FY27 ASSETS Non-Current Assets (A) Property, Plant and Equipment 2,414 5,851 5,657 (B) Capital Work-in-progress 3,170 1,747 2,425 (C) Right-of-Use Assets 374 428 401 (D) Other Intangible Assets 165 91 77 (E) Financial Assets (i) Investments 855 869 878 (ii) Trade Receivables 7 3 3 (iii) Loans 618 566 611 (iv) Other Financial Assets 91 119 119 (F) Other Non-Current Assets 469 377 539 (G) Deferred Tax Assets 73 140 117 Total Non – Current Assets 8,236 10,191 10,827 Current Assets (A) Inventories 2,410 3,856 3,701 (B) Financial Assets (i) Investments 4 6 11 (ii) Trade Receivables 10,988 10,725 10,620 (iii) Cash & Cash Equivalents 1,158 1,411 730 (iv) Bank Balances 3,086 1,300 1,370 (v) Loans 122 99 156 (vi) Other Financial Assets 108 54 48 (C) Other current assets 2,802 4,962 5,213 (D) Current Tax Assets (Net) - - 238 Total Current Assets 20,678 22,413 22,087 GRAND TOTAL – ASSETS 28,914 32,604 32,914 Historical Standalone Balance Sheet
Page 27
27 Historical Consolidated Financial Performance @Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 2,37,36,140) and shares held by Subsidiary companies: (No. of Shares- 43,78,740) INCOME STATEMENT (INR Mn) FY23 FY24 FY25 FY26 H1-FY27 Operating Income 19,896 23,479 27,371 29,148 13,752 Expenses 17,346 20,759 24,432 27,046 14,282 Operating EBITDA 2,550 2,720 2,939 2,102 (530) Operating EBITDA Margins (%) 12.82% 11.58% 10.74% 7.21% (3.85)% Depreciation 291 364 445 626 438 Finance Cost 92 121 135 240 184 Other Income 411 439 486 865 138 PBT before Exceptional Items 2,578 2,674 2,845 2,101 (1,014) Exceptional Items - - - 169 - PBT 2,578 2,674 2,845 1,932 (1,014) Share of Profit of equity accounted Investee 9 15 10 17 13 Tax 637 735 772 517 (204) Profit After Tax 1,950 1,954 2,083 1,432 (797) PAT Margins (%) 9.80% 8.32% 7.61% 4.91% (5.80)% Other Comprehensive Income (17) (3) 1 70 11 Total Comprehensive Income 1,933 1,951 2,084 1,502 (786) EPS Diluted (INR) @ 16.595 16.534 17.530 12.034 (6.490)
Page 28
28 Historical Consolidated Balance Sheet PARTICULARS (INR Mn) FY25 FY26 H1-FY27 EQUITIES & LIABILITIES Equity (A) Equity Share Capital 142 142 142 (B) Other Equity 11,937 13,248 12,336 Equity attributable to owners 12,079 13,390 12,478 Non Controlling Interest 16 13 -13 Total Equity 12,095 13,403 12,465 Non-Current Liabilities (A) Financial Liabilities (i) Borrowings 2,521 3,576 3,196 (ii) Lease liabilities 143 171 152 (iii) Other Financial Liabilities 133 125 112 (B) Provisions 208 302 303 (C) Deferred Tax Liabilities (Net) 88 88 80 (D) Other Non-Current Liabilities - - - Total Non – Current Liabilities 3,093 4,262 3,843 Current Liabilities (A) Financial Liabilities (i) Borrowings 510 968 1,236 (ii) Lease liabilities 53 107 105 (iii) Trade Payables 7,790 8,997 8,805 (iv) Other Financial Liabilities 944 880 1,179 (B) Other Current Liabilities 5,199 4,817 6,019 (C) Provisions 78 280 368 (D) Liabilities for current tax (Net) 107 85 13 Total Current Liabilities 14,681 16,134 17,725 GRAND TOTAL - EQUITIES & LIABILITES 29,869 33,799 34,033 PARTICULARS (INR Mn) FY25 FY26 H1-FY27 ASSETS Non-Current Assets (A) Property, Plant and Equipment 3,280 6,853 6,644 (B) Capital Work-in-progress 3,178 1,747 2,425 (C) Right-of-Use Assets 394 444 413 (D) Other Intangible Assets 203 140 126 (E) Goodwill 102 102 102 (F) Investment accounted using Equity Method 68 85 97 (G) Financial Assets (i) Investments 59 68 69 (ii) Trade Receivables 7 3 3 (iii) Other Financial Assets 154 175 170 (H) Deferred Tax Assets (Net) 77 144 121 (I) Other Non-Current Assets 536 445 609 (J) Non-Current Tax Assets 8 26 30 Total Non – Current Assets 8,066 10,232 10,809 Current Assets (A) Inventories 2,990 4,414 4,331 (B) Financial Assets (i) Investments 4 6 11 (ii) Trade Receivables 11,074 10,747 10,573 (iii) Cash & Cash Equivalents 1,493 1,846 1,153 (iv) Bank Balances 3,165 1,341 1,435 (v) Loans 53 66 78 (vi) Other Financial Assets 133 79 76 (C) Current Tax Assets (Net) 5 22 258 (D) Other Current Assets 2,886 5,046 5,309 Total Current Assets 21,803 23,567 23,224 GRAND TOTAL – ASSETS 29,869 33,799 34,033
Page 29
29 Revenues (INR Mn) Consolidated Historical Financial Performance 19,896 23,479 27,371 29,148 13,752 FY23 FY24 FY25 FY26 H1-FY27 Operating EBITDA (INR Mn) 2,550 2,720 2,939 2,102 (530) 12.82% 11.58% 10.74% 7.21% (3.85)% FY23 FY24 FY25 FY26 H1-FY27 EBITDA EBITDA Margins
Page 30
30 PAT (INR Mn) Consolidated Historical Financial Performance 1,950 1,954 2,083 1,432 (797) 9.80% 8.32% 7.61% 4.91% (5.80)% FY23 FY24 FY25 FY26 H1-FY27 PAT PAT Margins Net Debt / Equity (0.6) (0.4) (0.1) 0.1 0.1 FY23 FY24 FY25 FY26 H1-FY27
Page 31
31 Return Ratios Consolidated Historical Financial Performance Summary ▪ Roha Plant Capex impact ▪ West Asia crisis impacted gross working capital ▪ Reduced Profitability Future Actions ▪ Higher share of Industrial Products, Life cycle Services and Specialty Chemicals ▪ Continue disciplined Capital Allocation 23.3% 21.1% 18.7% 11.2% 30.0% 26.9% 22.0% 14.3% FY23 FY24 FY25 FY26 ROE ROCE ROE = Net Profit/Net worth, ROCE = EBIT/Capital Employed
Page 32
32 Working Capital Days Consolidated Historical Financial Performance Summary ▪ High proportion in Treatment Solution segment ▪ Impact of West Asia crisis in FY 26 Future Actions ▪ Increased business from Industrial Products, Lifecycle Services and Specialty Chemicals ▪ Increased share of International business ▪ Focus on improving Working Capital Cycle 91 99 94 91 FY23 FY24 FY25 FY26
Page 33
33 Market Data (Bloomberg – ION IN, Reuters – IONX.BO) S H A R E H O L D I N G P A T T E R N ( A s o n 3 0th S e p t e m b e r 2026) -25% -20% -15% -10% -5% 0% 5% 10% 15% 20% Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Jul-26 Aug-26 Sep-26 Ion Exchange Sensex 1 Y E A R S H A R E P R I C E M O V E M E N T ( U P T O 3 0t h S e p t e m b e r 2026) Promoter 25.1% Mutual Funds 12.9% Alternative Investment Funds, 2.8% Foreign Portfolio Investors, 4.9% Employee Trust, 16.2% Others, 38.1% P R I C E D ATA ( A s o n 30 t h S e p t e m b e r 2026) Face value (INR) 1.00 Market Price (INR) 411.10 52 Week H/L (INR) 485.80 / 312.30 Market Cap (INR Mn) 60,294.64 Equity Shares Outstanding (Mn) 146.67 1 Year Avg. trading volume (‘000) 482.25
Page 34
34 Disclaimer Ion Exchange (India) Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Ion Exchange (India) Limited (“Company” or “IONEX” ), which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward- looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. Valorem Advisors Disclaimer: Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valo rem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or im plied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review. For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-35075100 Email: ion@valoremadvisors.com To access the Investor Kit link and/or request a meeting click here: https://valoremadvisors.com/ion
Page 35
www.ionexchangeglobal.com www.ionexchangeglobal.com